Teva Goes After Mylan Over Copaxone Patents

Law360, New York (September 21, 2010, 4:38 PM EDT) -- Teva Pharmaceutical Industries Ltd. has accused Mylan Pharmaceuticals Inc. of infringing four patents related to the characterization of multiple sclerosis treatment Copaxone.

The Israel-based drugmaker filed a complaint Tuesday in the U.S. District Court for the Southern District of New York, following Mylan's abbreviated new drug application with the U.S. Food and Drug Administration to introduce a generic version of Copaxone.

According to Teva, the latest of the patents-in-suit expires in February 2020. Copaxone, also known as latiramer acetate injection, is the No. 1 prescribed treatment...
To view the full article, register now.